Literature DB >> 18657355

Progression of prostate cancer: multiple pathways to androgen independence.

Hong-Lin Devlin1, Maria Mudryj.   

Abstract

Prostate cancer remains one of the most commonly diagnosed cancers and a leading cause of cancer death in men. Initially, prostate tumors respond to hormonal therapies, but androgen-independent tumors refractory to these therapies emerge. Identifying the mechanisms responsible for the emergence of androgen independence has been the subject of multiple studies. This article reviews the multiple pathways that have been shown to promote androgen independence, including a recently described mechanism that involves androgen receptor proteolysis to a constitutively active ligand-independent isoform. Identifying the underlying mechanisms of androgen independence is crucial in the design of appropriate therapies for hormonally refractive neoplasms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657355     DOI: 10.1016/j.canlet.2008.06.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  40 in total

1.  Direct cooperation between androgen receptor and E2F1 reveals a common regulation mechanism for androgen-responsive genes in prostate cells.

Authors:  D M Altintas; M S Shukla; D Goutte-Gattat; D Angelov; J P Rouault; S Dimitrov; Jacques Samarut
Journal:  Mol Endocrinol       Date:  2012-07-06

2.  Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.

Authors:  Bulent Karabulut; Burcak Karaca; Harika Atmaca; Asli Kisim; Selim Uzunoglu; Canfeza Sezgin; Ruchan Uslu
Journal:  Mol Biol Rep       Date:  2010-03-28       Impact factor: 2.316

3.  HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

Authors:  I-Ju Yeh; Kyung Song; Bryan M Wittmann; Xiaodong Bai; David Danielpour; Monica M Montano
Journal:  Biochem J       Date:  2014-09-01       Impact factor: 3.857

4.  Aurora Kinase A Promotes AR Degradation via the E3 Ligase CHIP.

Authors:  Sukumar Sarkar; David L Brautigan; James M Larner
Journal:  Mol Cancer Res       Date:  2017-05-23       Impact factor: 5.852

5.  Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells.

Authors:  Huiqing Yuan; Charles Y F Young; Yuanyuan Tian; Zhifang Liu; Mengye Zhang; Hongxiang Lou
Journal:  Mol Cell Biochem       Date:  2010-02-11       Impact factor: 3.396

6.  Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.

Authors:  Belen Elguero; Geraldine Gueron; Jimena Giudice; Martin A Toscani; Paola De Luca; Florencia Zalazar; Federico Coluccio-Leskow; Roberto Meiss; Nora Navone; Adriana De Siervi; Elba Vazquez
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

7.  Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.

Authors:  Rute B Marques; Natasja F Dits; Sigrun Erkens-Schulze; Wytske M van Weerden; Guido Jenster
Journal:  PLoS One       Date:  2010-10-19       Impact factor: 3.240

8.  ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.

Authors:  Sakthivel Muniyan; Siu-Ju Chen; Fen-Fen Lin; Zhengzhong Wang; Parmender P Mehta; Surinder K Batra; Ming-Fong Lin
Journal:  Cell Signal       Date:  2015-08-06       Impact factor: 4.315

9.  Antiproliferative effect of a synthetic aptamer mimicking androgen response elements in the LNCaP cell line.

Authors:  S Kouhpayeh; A R Einizadeh; Z Hejazi; M Boshtam; L Shariati; M Mirian; L Darzi; M Sojoudi; H Khanahmad; A Rezaei
Journal:  Cancer Gene Ther       Date:  2016-07-01       Impact factor: 5.987

Review 10.  On the origins of the androgen receptor low molecular weight species.

Authors:  Maria Mudryj; Clifford G Tepper
Journal:  Horm Cancer       Date:  2013-07-17       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.